| fluoxetine / Generic mfg. |
NCT00913718: To Demonstrate the Relative Bioavailability of Geneva and Dista (Prozac) 20 mg Fluoxetine Hydrochloride Capsules (Pulvules) In Healthy Adult Males Under Fasting Conditions |
|
|
| Completed | 1 | 46 | NA | Fluoxetine Hydrochloride 20 mg Capsules (Geneva Pharmaceutical, Inc.), Prozac Fluoxetine Hydrochloride 20 mg Capsules (Dista) | Sandoz | Depression | 07/96 | 07/96 | | |
NCT00913588: To Demonstrate the Relative Bioavailability of Geneva and Dista (Prozac) 20 mg Fluoxetine Hydrochloride Capsules (Pulvules) In Healthy Adult Males Under Fed and Fasted Conditions |
|
|
| Completed | 1 | 24 | NA | Fluoxetine HCl 20 mg Capsules Under Fasting Conditions (Geneva Pharmaceutical, Inc.), Fluoxetine HCl 20 mg Capsules Under Fed Conditions (Geneva Pharmaceutical, Inc.), Prozac Fluoxetine HCl 20 mg Capsules Under Fed Conditions (Dista) | Sandoz | Depression | 08/96 | 08/96 | | |
NCT00947076: To Demonstrate the Relative Bioavailability of Fluoxetine Hydrochloride Capsules, 40 mg |
|
|
| Completed | 1 | 30 | NA | Fluoxetine Hydrochloride Capsules, 40 mg (Geneva Pharmaceutical, Inc), Fluoxetine Hydrochloride Capsules, 40 mg (Prozac) (Eli Lilly) | Sandoz | Depression | 04/01 | 04/01 | | |
NCT01247285: 90 mg Fluoxetine Hydrochloride Capsules Under Non-Fasting Conditions |
|
|
| Completed | 1 | 26 | US | Fluoxetine Hydrochloride, PROZAC WEEKLY®, Fluoxetine Hydrochloride (generic name) | Teva Pharmaceuticals USA | Healthy | 07/01 | 07/01 | | |
NCT01247272: 90 mg Fluoxetine Hydrochloride Capsules Under Fasting Conditions |
|
|
| Completed | 1 | 26 | US | Fluoxetine Hydrochloride, PROZAC WEEKLY®, Fluoxetine Hydrochloride (generic name) | Teva Pharmaceuticals USA | Healthy | 07/01 | 07/01 | | |
NCT01166087: Bioequivalence Study of Fluoxetine Hydrochloride Delayed-Release Capsules 90 mg of Dr. Reddy's Under Fed Condition |
|
|
| Completed | 1 | 54 | RoW | Fluoxetine Hydrochloride, Prozac ® weekly 90 mg Delayed Release Capsules | Dr. Reddy's Laboratories Limited | Healthy | 03/06 | 09/06 | | |
NCT01166100: Bioequivalence Study of Fluoxetine Hydrochloride Delayed-Release Capsules, 90 mg of Dr. Reddy's Under Fasting Condition |
|
|
| Completed | 1 | 54 | RoW | Fluoxetine Hydrochloride, Prozac ® weekly 90 mg Delayed-Release Capsules | Dr. Reddy's Laboratories Limited | Healthy | 03/06 | 08/06 | | |
NCT00649636: Fasting Study of Fluoxetine Capsules 40 mg and Prozac Pulvules 40 mg |
|
|
| Completed | 1 | 32 | US | Fluoxetine Capsules 40 mg, Prozac Pulvules 40 mg | Mylan Pharmaceuticals Inc | Healthy | 04/06 | 04/06 | | |
| Completed | 1 | 10 | Europe | Clopidogrel then fluoxetine+clopidogrel, Fluoxetine+clopidogrel then clopidogrel | Centre Hospitalier Universitaire de Saint Etienne | Healthy | 05/09 | 05/09 | | |
NCT01243957: A Study to Measure if There is Any Difference in How the Body Breaks Down or Inactivates Either Fluoxetine or LY2216684 When Both of These Medicines Are Given Together. |
|
|
| Completed | 1 | 20 | US | LY2216684, Fluoxetine | Eli Lilly and Company | Major Depressive Disorder | 01/11 | 01/11 | | |
| Completed | 1 | 98 | US | SSRI, Lexapro, escitalopram, Prozac, fluoxetine, Sertraline, Zoloft, CBT, CT, Cognitive Therapy | University of Pittsburgh, The Pittsburgh Foundation, National Institute of Mental Health (NIMH) | Major Depressive Disorder | 07/11 | 07/11 | | |
NCT01569126: A Study of LY110140 in Healthy Japanese Male Participants |
|
|
| Completed | 1 | 56 | Japan | LY110140, Fluoxetine Hydrochloride, Prozac, Sarafem, Placebo | Eli Lilly and Company | Healthy Volunteer | 09/12 | 09/12 | | |
NCT00489593: Olanzapine in Patients With Advanced Cancer and Weight Loss |
|
|
| Completed | 1 | 57 | US | Olanzapine, Zyprexa, Fluoxetine, Symbyax | M.D. Anderson Cancer Center | Advanced Cancer, Weight Loss | 12/13 | 12/13 | | |
NCT01967979: A Study of the Effect of Multiple Doses of Itraconazole and Fluoxetine on the Pharmacokinetics of a Single Dose of RO5285119 in Healthy Subjects |
|
|
| Completed | 1 | 28 | Europe | RO5285119, fluoxetine, itraconazole | Hoffmann-La Roche | Healthy Volunteer | 12/13 | 12/13 | | |
NCT02965274: Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Fluoxetine Tablets Under Fed Conditions |
|
|
| Completed | 1 | 26 | US | Torrent's Fluoxetine Tablets, Warner Chilcott LLC's Sarafem Tablet | Torrent Pharmaceuticals Limited | Healthy Subjects | 01/14 | 01/14 | | |
NCT02965261: Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Fluoxetine Tablet Under Fasting Conditions |
|
|
| Completed | 1 | 26 | US | Torrent's Fluoxetine Tablets, Warner Chilcott LLC Sarafem Tablets | Torrent Pharmaceuticals Limited | Healthy Subjects | 01/14 | 01/14 | | |
2017-000687-16: Novel avenues for the rescue of intellectual disability in Down syndrome strategia farmacologiche per migliorare la disabilit¿ intellettiva nella sindrome di Down |
|
|
| Not yet recruiting | 1 | 20 | Europe | prozac, 25970029, Oral solution, PROZAC - 20 MG/5 ML SOLUZIONE ORALE 1 FLACONE IN VETRO DA 60 ML | AOU FEDERICO II, Universit¿ Alma Studiorum Bologna | DOWN SYNDROME SINDROME DI DOWN, chromosome 21 trisomy trisomia del cromosoma 21, Diseases [C] - Nervous System Diseases [C10] | | | | |
ACTRN12619001413112: A DDI Study to Evaluate the Effects of Itraconazole and Fluoxetine on AK0529 in Healthy Volunteers |
|
|
| Completed | 1 | 28 | | | Ark Biosciences Pty Ltd, Ark Biosciences Pty Ltd | Respiratory Syncytial Virus Infection | | | | |
| Withdrawn | 1 | 0 | US | Fluoxetine, Prozac, Placebo, "sugar" pill | University of California, Los Angeles, City of Hope Medical Center | Cognitive Dysfunction | 10/20 | 10/20 | | |
ChiCTR1900026481: Bioequivalence pre-test of fluoxetine hydrobromide in healthy humans |
|
|
| Not yet recruiting | 1 | 24 | | T ;R ;T ;R | Changsha Third Hospital; Changsha Third Hospital, Offer by the sponsor | Adult depression | | | | |
NCT05532332: Bioequivalence Study of Fluoxetine in Healthy Adult Subjects Under Fasting Condition |
|
|
| Completed | 1 | 34 | RoW | Fluoxetine 10 mg capsules, Test product (T), Prozac® 10 mg capsules, Reference product (R) | Future University in Egypt | Healthy Subjects | 02/21 | 02/21 | | |
NCT04570449: Fluoxetine to Reduce Hospitalization From COVID-19 Infection (FloR COVID-19) |
|
|
| Withdrawn | 1 | 0 | US | Fluoxetine, Placebo | Milton S. Hershey Medical Center | Covid19 | 11/21 | 12/21 | | |
NCT05789186: Clinical Study of Cang Ai Volatile Oil (CAVO) on Mild to Moderate Depression in Children and Adolescents |
|
|
| Recruiting | 1 | 108 | RoW | CAVO aromatherapy patch at 3% concentration+Fluoxetine hydrochloride mimetic, Fluoxetine hydrochloride tablet+CAVO aromatherapy patch at 0.1% concentration, Fluoxetine hydrochloride mimetic+CAVO aromatherapy patch at 0.1% concentration | Chen Qian | Depression | 09/23 | 01/24 | | |
NCT05634707: Evaluation of Fluoxetine and Cytotoxic Lysosomal Stress in Glioma (FLIRT) |
|
|
| Recruiting | 1 | 30 | US | Fluoxetine, Temozolomide | Duke University | Primary Brain Tumor, Brain Tumor, Recurrent | 12/25 | 06/26 | | |
| Recruiting | 1 | 60 | US | Placebo Oral Tablet, Fluoxetine, DHEA, dehydroepiandrosterone, Fluoxetine and DHEA, Prozac, dehydroepiandrosterone | University of Maryland, Baltimore | Type 1 Diabetes Mellitus | 02/25 | 12/26 | | |
NCT04850222: Fluoxetine Mitigation Mental Health Study for Patients With Musculoskeletal Trauma |
|
|
| Recruiting | 1 | 150 | US | Fluoxetine, Calcium | University of Florida | Musculoskeletal Injury | 06/24 | 06/24 | | |
NCT01672255: Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus (DM) |
|
|
| Recruiting | 1 | 64 | US | Fluoxetine, Prozac, Placebo control | University of Maryland, Baltimore, National Heart, Lung, and Blood Institute (NHLBI) | Type 1 Diabetes, Hypoglycemia Associated Autonomic Failure | 12/24 | 12/25 | | |
NCT06225011: Fluoxetine for the Modification of Colorectal Tumor Immune Cells Before Surgery in Patients With Colorectal Cancer |
|
|
| Not yet recruiting | 1 | 10 | US | Fluoxetine | Jonsson Comprehensive Cancer Center | Colorectal Adenocarcinoma | 12/25 | 12/26 | | |
ChiCTR2300074818: Acupuncture plus Chinese herbal formula for post-stroke depression: A protocol for randomized controlled trial |
|
|
| Not yet recruiting | 1 | 64 | | Acupincture: Main points: Yintang, Baihui, Shuigou, Neiguan (bilateral), Sanyinjiao (affected side); matching points: Jiquan, Chize, Weizhong, Hegu, Qiuxu, Tiantu, based on the patient's accompanying symptoms of stroke. 30 mintues for one time, and once a day for four weeks. Chinese Herbal medicine: The decoction of Yu-Dian Tang will be administered orally at a dose of 150ml two times a day for four weeks. One is before breakfast and another one after dinner. The supply of the herbs will be by Heilongjiang Mental Health Hospital and no endangered species or restricted herbs will be used in the study. All the decoctions will be boiled by the TCM pharmacy in Heilongjiang Mental Health Hospital. ;Patients in the control group will receive orally administered Fluoxetine (FLX) for four weeks. The dose is initiated at 10mg per day and the different optimal dose will be escalated for every patient within one week based on his/her response. | the Second Affiliated Hospital of Heilongjiang University of Chinese Medicine; the Second Affiliated Hospital of Heilongjiang University of Chinese Medicine, Postdoctoral Scientific Research Developmental Fund of Heilongjiang Province (LBH-Q21180) | post-stroke depression | | | | |
